GSK to manufacture 60 million doses of Novavax vaccine for the UK
Pharma company will provide fill and finish manufacturing capacity at its Barnard Castle facility as early as the beginning of May 2021
GlaxoSmithKline has agreed in principle to support Novavax in the production of up to 60 million doses of its COVID-19 vaccine candidate, NVX-CoV2373, for use in the UK by providing fill and finish manufacturing capacity at its Barnard Castle facility in England.
Fill and finish is the completion stage of vaccine manufacturing, which involves preparing vials of the final vaccine and packaging them for distribution and use. Operations could start as early as May 2021.
GSK is now preparing the Barnard Castle site in the north east of England, including a rapid technology transfer with Novavax. The site is a specialised facility that produces GSK pharmaceutical and vaccine products.
GSK said it intends to manufacture most, if not all, of the 60 million vaccine doses the UK Government has secured under an advance purchase agreement with Novavax.
"We have ensured that we can deliver these volumes without impacting supply of our other vital medicines and vaccines, and without disruption to the other COVID-19 collaborations GSK is engaged in globally," said Roger Connor, President, GSK vaccines.
The protein antigen component of NVX-CoV2373 is also produced in the north east of England by Novavax' manufacturing partner, Fujifilm Diosynth Biotechnologies, at its site in Billingham, Stockton-on-Tees.
The Novavax vaccine candidate has demonstrated strong potential efficacy in Phase III clinical trials, including against the B.1.1.7 variant circulating in the UK. Submission of the vaccine for review by regulatory authorities in the UK is expected during the second quarter.
In a statement, UK Prime Minister Boris Johnson said GSK's investment showed the "strength of UK manufacturing" and would help with the nation's vaccine rollout, including the targets of offering a first jab to all over 50s by 15 April and all adults by the end of July.
GSK is collaborating with several organisations around the world on COVID-19 vaccines by providing access to its adjuvant technology. The use of an adjuvant can be of particular importance in a pandemic as it may reduce the amount of vaccine protein required per dose, allowing more vaccine doses to be produced and contributing to protecting more people.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance